The relationship between controllability, optimal testing resource allocation, and incubation-latent period mismatch as revealed by COVID-19

Jeffery Demers[1,2,*], William F. Fagan[2], Sriya Potluri[2], and Justin M. Calabrese[1,2]

[1]Center for Advanced Systems Understanding (CASUS), Görlitz, Germany
[2]Dept. of Biology, University of Maryland, College Park, MD, USA
[*]Corresponding author; Email: jdemers@umd.edu

Abstract

The severe shortfall in testing supplies during the initial phases of the COVID-19 pandemic and ensuing struggle to control disease spread have affirmed the need to plan rigorous optimized supply-constrained resource allocation strategies for the next inevitable novel disease epidemic. To address the challenge of optimizing limited resource usage in the face of complicated disease dynamics, we develop an integro partial differential equation disease model which incorporates realistic latent, incubation, and infectious period distributions along with limited testing supplies for identifying and quarantining infected individuals, and we analyze the influence of these elements on controllability and optimal resource allocation between two testing strategies, 'clinical' targeting symptomatic individuals and 'non-clinical' targeting non-symptomatic individuals, for reducing total infection sizes. We apply our model to not only the original, delta, and omicron COVID-19 variants, but also to generic diseases which have different offsets between latent and incubation period distributions which allow for or prevent varying degrees of presymptomatic transmission or preinfectiousness symptom onset. We find that factors which reduce controllability generally call for reduced levels of non-clinical testing, while the relationship between symptom onset, controllability, and optimal strategies is complicated. Although greater degrees of presymptomatic transmission reduce disease controllability, they may enhance or reduce the role of non-clinical testing in optimal strategies depending on other disease factors like overall transmissibility and latent period length. Our model allows a spectrum of diseases to be compared under the same lens such that the lessons learned from COVID-19 can be adapted to resource constraints in the next emerging epidemic and analyzed for optimal strategies under a consistent mathematical framework.

1 Introduction

Since its declaration as a global pandemic in March 2020 (1), COVID-19 has caused over 600 million cumulative infections and 6 million deaths (2). This loss of life and productivity together with ubiquitous lockdowns and mobility restrictions have resulted in devastating socioeconomic consequences worldwide (3, 4). The particularly severe costs of lockdowns underscore the need for effective large scale test-trace-quarantine programs to combat emerging disease epidemics and save

lives while keeping society open and functioning. Unfortunately, for an emerging epidemic caused by a novel pathogen, testing supplies and health care infrastructure may be inadequate to meet demand as health agencies struggle to implement new techniques and technologies at population-wide scales. During the initial phases of the COVID-19 pandemic, for example, testing capacities fell well-short of the levels required to monitor populations and test all suspected cases, while delays due to processing backlogs limited the usefulness of the small number of tests that were actually available (5, 6). Even now, 3 years after the emergence of COVID-19, supplies have struggled to meet the demand of case surges associated with new COVID variants (6).

When COVID resources have fallen short of demand, experts and health agencies have recommended the prioritization of testing supplies to the most severely symptomatic and vulnerable patients most typically found in clinical health care settings, rather than to non-clinical cases associated with mildly or asymptomatic individuals and population monitoring programs (6, 7, 8). This strategy seeks to maximize the utility of the few resources available by limiting the amount 'wasted' on individuals who are not infected, but in the process excludes the possibility of slowing disease spread by identifying and quarantining non-symptomatic infected individuals (9). Achieving an ideal balance between clinical and non-clinical resource allocation is especially pertinent for a disease like COVID-19, where undetected presymptomatic transmission caused by mismatched latent and incubation periods (10, 11) as well as potentially large numbers of undetected totally asymptomatic spreaders (12, 13, 14, 15) present significant barriers to controllability. Given the complexity of real-world disease dynamics with features like presymptomatic transmission and symptom-based interventions, simplified compartmental mathematical models provide powerful tools for analyzing and optimizing control strategies in the face of resource limitations.

Many previous compartmental models have been developed to analyze and optimize COVID-19 control strategies like testing and quarantine. Generally, models handle presymptomatic transmission by one of two broad schemes. One class of models simply ignores the potential for presymptomatic transmission by having infected individuals transition from an exposed non-symptomatic non-infectious compartment to an infectious symptomatic compartment, often with an additional infection channel comprised of permanently asymptomatic infected individuals. Such models have been used to analyze testing, contact tracing, and quarantine control strategies (16, 17), particularly in the context of limited resource constraints (18), along with vaccination control (19) and

non-pharmaceutical interventions like masking and social distancing (20, 21). Although useful as simple baseline examples, these models may overestimate the efficacy of symptom-based COVID-19 controls due to the absence of presymptomatic transmission. Another class of models includes a presymptomatic compartment where individuals are infectious but not yet symptomatic before transitioning to an infectious symptomatic class (22, 23, 24, 25). This approach, although more realistic, presents challenges when interpreting results for real world decision making via comparisons to the simpler class of models. Specifically, when multiple infectious stages are incorporated in an ordinary differential equation model, the total infectious period is no longer exponentially distributed (as occurs for a single infectious stage), but is instead more similar to a gamma or Wielbul distribution (26), and such non-exponential distributions have been shown to be more difficult to control with identification-isolation strategies as compared to exponential distributions (27). Thus, it is unclear if differences in output between models with presymptomatic compartments and that of simpler models are due to presymptomatic transmission or to non-exponential infectious periods, and this presents a barrier to interpreting model results for real-world decision making. Of further complication, when a totally asymptomatic infection channel is included, one must either add a fictitious presymptomatic compartment for this class or accept a major qualitative difference between the never symptomatic and eventually symptomatic infectious period distributions (exponential vs non-exponential). Finally, this class of models can not be adapted to other diseases for which infectiousness peaks well after symptom onset (such as with the 2003 SARS coronavirus (28, 29)) without significant changes to model structure, and this complicates any comparative mathematical analysis of diseases which are fundamentally similar to one another aside changes in the offset between their incubation and latent period. This deficit may be particularly problematic for using mathematical models to inform real-world control strategies for new emerging epidemics based on the lessons learned from COVID-19.

We address these shortcomings by developing a partial integro differential equation model which utilizes the age of infection to decouple symptom status from specific model compartments. Our model is general in its ability to incorporate any latent, incubation, and infectious period distribution, regardless of shape or relative timings of means, and is utilized to analyze the original, delta, and omicron variants as well as a spectrum of other generic diseases all under a single lens. We incorporate a testing and quarantine control strategy which uses testing resources to identify

infected individuals and remove them from the population, accounting for factors like contact tracing, limited population accessibility, and biases towards test-positive results. Our control assumes a fixed maximum testing capacity which must be allocated between clinical testing targeted at symptomatic individuals and non-clinical testing targeted at pre and asymptomatic individuals, and we analyze how controllability and optimal allocation strategies for reducing total infection size and behave as functions of resource availability, testing quality, and disease characteristics. In general, we find that most factors which reduce controllability also call for a smaller share of resources to be devoted to non-clinical testing. However, although presymptomatic transmission is found to reduce controllability, whether or not it reduces the role of non-clinical testing depends on a complicated relationship between latent-incubation offset, disease transmissibility, and latent period length. In particular, we find that diseases which lack presymptomatic transmission do not necessarily call for a reduction in non-clinical testing compared to diseases with presymptomatic transmission. Together, these results highlight how intuition for disease control strategies based on qualitative disease characteristics may fail and emphasize the need for mathematical modeling in order to prepare for future epidemics.

2 Methods

We extend the previous ordinary differential equation (ODE) SEIR testing and quarantine model of Calabrese and Demers (18) to a system of integro-partial differential equations (IPDE) which explicitly incorporate the age of infection for infected classes. While our primary focus is COVID-19, including the orginal, delta, and omicron variants, our system is general in its ability to account for any set of latent, incubation, and infectiousness periods.

2.1 Model outline

2.1.1 Uncontrolled transmission model

We assume a homogeneously mixed system of N total susceptible, exposed, infectious, and recovered individuals. Exposed and infectious classes are partitioned into those who will remain permanently asymptomatic throughout the course of the infection and those who will eventually become symptomatic at some point before recovery. Here, we take "asymptomatic" to mean genuinely exhibiting

no symptoms or exhibiting symptoms so minor that one would not typically consider themselves ill or seek medical attention, and "symptomatic" to mean exhibiting visually identifiable symptoms with moderate to critical illness. Upon infection, initially susceptible individuals S will enter either the exposed permanently asymptomatic class E_A or the exposed eventually symptomatic class E_Y with probabilities f_A and f_Y, respectively. While in an exposed class, individuals are infected but not yet infectious and are thus unable to transmit the disease to others. To account for the possibility of non-exponential waiting times between infection sages, we continuously index exposed classes with the age of infection x. The number of individuals in the exposed permanently asymptomatic class at time t who have been infected for between x and $x + dx$ units of time is denoted $e_A(t, x)dx$ such that the total number of exposed permanently asymptomatic individuals $E_A(t)$ is given by $E_A(t) = \int_0^\infty dx\, e_A(t, x)$. The age of infection-indexed exposed eventually symptomatic class $e_Y(t, x)$ is defined analogously. Permanently asymptomatic and eventually symptomatic exposed individuals with infection age x transition to their respective infectious classes $a(t, x)$ and $y(t, x)$ at rate $\varepsilon(x)$. Infectious individuals enter into the recovered class R where they are no longer infectious and are assumed to attain permanent immunity at age of infection dependent recovery rate $r(x)$. Although there is some evidence suggesting that eventually symptomatic and permanently asymptomatic individuals recover from COVID-19 at different rates, disease progression is asymptomatic individuals is poorly understood, and conflicting studies have shown faster, similar, and slower viral clearance rates in asymptomatic versus symptomatic cases (30, 31). We therefore, for simplicity, take $r(x)$ to be equivalent for permanently asymptomatic and eventually symptomatic infections. Likewise, we are aware of only one study suggesting different transitions rates from the exposed to infectious class for permanently asymptomatic versus eventually symptomatic individuals (10), but the corresponding average waiting times differ by only 1 part in 20, so we assume exposed to infectious transitions rates to be independent of the eventual presence or lack of symptoms. The dynamical equations for the uncontrolled transmission model are as follows:

$$\dot{S}(t) = -\lambda_A\, \beta \frac{A(t)}{N} S(t) - \lambda_Y\, \beta \frac{Y(t)}{N} S(t) \tag{1a}$$

$$\partial_t e_A(t, x) + \partial_x e_A(t, x) = -\varepsilon(x)\, e_A(t, x) \tag{1b}$$

$$e_A(t, 0) = f_A \left(\lambda_A\, \beta \frac{A(t)}{N} S(t) + \lambda_Y\, \beta \frac{Y(t)}{N} S(t) \right) \tag{1c}$$

$$
\begin{aligned}
\partial_t e_Y(t,x) + \partial_x e_Y(t,x) &= -\varepsilon(x)\, e_Y(t,x) && \text{(1d)}\\
e_Y(t,0) &= f_Y\left(\lambda_A\, \beta \frac{A(t)}{N} S(t) + \lambda_Y\, \beta \frac{Y(t)}{N} S(t)\right) && \text{(1e)}\\
\partial_t a(t,x) + \partial_x a(t,x) &= \varepsilon(x)\, e_A(t,x) - r(x) a(t,x) && \text{(1f)}\\
a(t,0) &= 0 && \text{(1g)}\\
\partial_t y(t,x) + \partial_x y(t,x) &= \varepsilon(x)\, e_Y(t,x) - r(x) y(t,x) && \text{(1h)}\\
y(t,0) &= 0 && \text{(1i)}\\
\dot{R}(t) &= \int_0^\infty dx \left(r(x) a(t,x) + r(x) y(t,x)\right) && \text{(1j)}
\end{aligned}
$$

$$
\begin{aligned}
E_A(t) = \textstyle\int_0^\infty dx\, e_A(t,x), \quad E_Y(t) = \textstyle\int_0^\infty dx\, e_Y(t,x), \qquad \text{(1k)}\\
A(t) = \textstyle\int_0^\infty dx\, a(t,x), \quad Y(t) = \textstyle\int_0^\infty dx\, y(t,x).
\end{aligned}
$$

In the above equations, overdots denote ordinary derivatives with respect to time t, β denotes the average number of contacts made per unit time by an individual, N is the total population size, and λ_A and λ_Y denote the transmission probability per susceptible-infectious contact for the never symptomatic and eventually symptomatic classes, respectively (for simplicity, we assume transmission probability to be independent of the age of infection). The boundary terms $e_A(t,0)$ and $e_Y(t,0)$ denote the rates of newly generated infections and thus represent to individuals with infection age $x = 0$. The boundary terms $a(t,0)$ and $y(t,0)$ are zero due to the fact that every infected individual will spend at least some time in an exposed class before becoming infectious and will therefore never enter an infectious class with an infection age $x = 0$. The integrals in Eq. (1k) relate the total number of individuals in an infected class to the corresponding distribution over the age of infection.

2.1.2 Symptom onset

The model in Eq. (1) makes no assumptions regarding the onset of symptoms in infected individuals. This modeling choice is based on the fact that the natural dynamics of disease transmission (absent of interventions or controls explicitly correlated with symptom status) depend fundamentally on infectious states rather than symptom states. In our IPDE model, symptoms are an incidental

background state which need not be represented by separate pre and post symptom onset compartments for each infected compartment as would be required in an ordinary differential equation (ODE) model. We utilize the age of infection in the eventually symptomatic classes to the define the symptomatic population $X_S(t)$ by the following integral:

$$X_S(t) = \int_0^\infty dx\Big(P_e(x)e_Y(t,x) + P_y(x)y(t,x)\Big). \tag{2}$$

The functions $P_e(x)$ and $P_y(x)$ denote the respective probabilities for exposed and infectious individuals to show symptoms by infection day x. These probabilities likewise determine the non-symptomatic infected population $X_N(t)$ as follows:

$$X_N(t) = E_A(t) + A(t) + \int_0^\infty dx\Big(\big(1 - P_e(x)\big)e_Y(t,x) + \big(1 - P_y(x)\big)y(t,x)\Big). \tag{3}$$

The non-symptomatic infected population is comprised of all never-symptomatic infected individuals plus the eventually symptomatic infected individuals who are not yet showing symptoms.

In our simulations, we consider two assumptions for $P_e(x)$ and $P_y(x)$, "correlated symptoms" and "incubation symptoms:"

$$\begin{aligned} &\text{Correlated Symptoms:} && P_e(x) = 0, P_y(x) = 1. \\ &\text{Incubation Symptoms:} && P_e(x) = P_y(x) = \textstyle\int_0^x dx' f_I(x'). \end{aligned} \tag{4}$$

The correlated symptoms assumption defines symptom onset to occur in perfect correlation with infectiousness onset. Here, there is no possibility of pre-symptomatic transmission or pre-infectious symptom onset, and the symptomatic population is the entire eventually symptomatic infectious class. This assumption is equivalent to the symptom assumptions of our previous ODE testing and quarantine COVID-19 model in (18). The incubation symptoms assumptions defines $P_e(x)$ and $P_y(x)$ to be the cumulative distribution function of an incubation period distribution $f_I(x)$. Here, $f_I(x)dx$ denotes the probability for an eventually symptomatic individual to begin showing symptoms between age of infection x and $x + dx$. The flow diagram in Fig. 1 summarizes the progression of infectious and symptomatic states in the uncontrolled transmission model.



Figure 1: Schematic indicating the flow of infectious and symptomatic states in our uncontrolled transmission. Upon infection, susceptible individuals S move into either the never symptomatic exposed class E_A or the eventually symptomatic exposed class E_Y with an initial age of infection $x = 0$. As individuals linger in the exposed classes, their ages of infection increase, and transitions to the never symptomatic infectious A and eventually symptomatic infectious Y occur at infection age dependent transition rate $\varepsilon(x)$ Infectious individuals then transition to the recovered class R at infection age dependent transition rate $r(x)$. Symptom status appears as background state indicated by the red an green boxes. For eventually symptomatic exposed and infectious individuals with infection age x, a fraction $P_e(x)$ and $P_y(x)$, respectively, will be in the symptomatic state X_S, while the remaining fractions $1-P_e(x)$ and $1-P_y(x)$ will be in the non-symptomatic state X_N. The never symptomatic classes E_A and A are permanently asymptomatic and remain in the non-symptomatic state X_N until recovery.

2.1.3 Testing and quarantine transmission model

We adapt the resource allocation testing and quarantine control framework from the ODE model of (18) to our IPDE disease model. Testing identifies and transfers infected individuals to a quarantine class Q where they remain isolated from contacts until recovery and are unable to generate new transmissions. We assume a finite testing resource represented by the testing capacity C, defined as the maximum per capita number of tests able to be administered and processed per day. A fraction ρ of the testing capacity is allocated to non-clinical testing for identifying non-symptomatic infected individuals, while the remaining fraction $1-\rho$ is allocated to clinical testing for identifying symptomatic infected individuals. Clinical testing is conducted only at hospitals and medical centers specifically for those showing visually identifiable symptoms, while non-clinical testing is accessible to the general public. The actual rate at which tests are administered and processed for the two testing categories is dependent on the *testing demand*, i.e. to the number of people eligible for and actively seeking testing. Here, we provide the functional forms of test administration and processing rates for clinical and non-clinical testing and sketch the reasoning behind their formulation. Further details are elucidated in (18).

The average time required for a non-clinical test to be administered and processed for a single individual is denoted τ_N such that the average administration and processing rate is given by $1/\tau_N$:

$$\tau_N^{-1} = \begin{cases} 0, & C = 0 \text{ or } \rho = 0 \\ \left[\tau + \kappa \frac{X_N(t) + \left(1-\eta\right)\left(S(t)+U(t)\right)}{\rho C N}\right]^{-1}, & \text{otherwise} \end{cases} \tag{5}$$

Non-clinical testing enters the disease model by transferring a fraction κ of the never symptomatic and eventually symptomatic not yet showing symptoms populations to the quarantined class Q at rate τ_N^{-1}. The case $C = 0$ corresponds to no testing capacity and thus no control, while the case $\rho = 0$ corresponds to all resources being devoted to clinical testing which reduces the non-clinical testing rate to zero. The quantity τ is the *intrinsic testing time*, defined as average time required for an individual get to a testing center, get tested, and receive results absent of delays or backlogs due to other patents. We take this value to be equal to one day. The testing demand for non-clinical testing is defined as a fraction κ the non-symptomatic population $X_N(t)$ in Eq. (3) as well as a fraction $\kappa(1-\eta)$ of the uninfected population $S(t)+U(t)$. Here, $U(t)$ represents individuals who

were previously infected and subsequently recovered without being tested and are thus unaware that they have immunity (we assume recovered individuals who were tested and quarantined know that they have immunity and therefore exclude themselves from future testing). The *accessibility parameter* $\kappa \in (0, 1]$ represents the fraction of the total population open to and compliant with non-clinical testing, and the *concentration parameter* $\eta \in [0, 1)$ represents the degree to which testing is focused on or biased towards infected individuals. A purely random population monitoring program which reaches all members of the population corresponds to $\kappa = 1$ and $\eta = 0$. Any factor which influences a given test will be more likely applied to an infected individual as compared to purely random sampling will increase η. For example, those who suspect a recent disease exposure may be both more likely to seek testing and more likely to test positive compared a randomly selected individual, and this influence will focus testing towards the X_N population and away from the $S+U$ population. Likewise, a highly effective contact tracing program may result in a relatively large value of η, but there may be many individuals unwilling to participate in government or health agency efforts, so the corresponding value of κ may be relatively small. Generally, the differing behavioral characteristics of individuals and differing testing policies of local governments unique to differing regions will correspond to a variety of concentration and accessibility levels, so we will analyze model results for a wide array of κ and η values. The analysis in (18) shows that η can be estimated from data comparing test-positive to disease prevalence rates, and that $\eta = 0.95$ is an upper bound on optimistically achievable values.

The average time required for a clinical test to be administered and processed for a single symptomatic individual is denoted τ_C such that the average administration and processing rate is given by $1/\tau_C$:

$$\tau_C^{-1} = \begin{cases} 0, & C = 0 \text{ or } \rho = 1 \\ \left[\tau + \frac{X_S(t)}{(1-\rho)CN}\right]^{-1}, & \text{otherwise} \end{cases} \tag{6}$$

Clinical testing enters the disease model by transferring symptomatic individuals to the quarantine class Q at rate τ_C^{-1}. The case $C = 0$ corresponds to no control, while the case $\rho = 1$ corresponds to all resources being devoted to non-clinical testing which reduces the clinical testing rate to zero. In contrast to non-clinical testing, clinical testing is assumed to have full concentration on and

full accessibility to the target infected population, meaning that the testing demand is comprised only of the symptomatic population X_S and includes no uninfected individuals. We base this on the assumption that all individuals in the eventually symptomatic classes who are currently showing symptoms are all ill enough to seek medical attentions (full advisability), and that due to the presence of strong visually identifiable symptoms and the lack of secondary diseases in our model, there is no chance of using a clinically allocated test on an uninfected individual (full concentration). In this sense, clinical testing acts as a verification tool, while non-clinical testing acts as an identification tool.

For both testing types, when testing demand is very low, tests are administered and processed at maximum rates $\tau_C^{-1} \approx \tau^{-1}$ and $\tau_N^{-1} \approx \tau^{-1}$ per individual, and the total number of clinical tests conducted per day grows linearly with the size of the symptomatic population. As demand increases, supply limitations and patient backlogs cause τ_C^{-1} and τ_N^{-1} to decrease towards zero, and the total number of clinical and non-clinical tests conducted per day saturates to $(1-\rho)CN$ and ρCN,respectively, as testing demand approaches infinity. The full model equations with testing and quarantine control are given in Eq. (7) and a corresponding flow diagram is given in Fig. 2. Table 1 summarizes the definitions of all control-related parameters.

$$\dot{S}(t) = -\lambda_A\,\beta\frac{A(t)}{N-Q(t)}S(t) - \lambda_Y\,\beta\frac{Y(t)}{N-Q(t)}S(t) \tag{7a}$$

$$\partial_t e_A(t,x) + \partial_x e_A(t,x) = -\varepsilon(x)\,e_A(t,x) - \kappa\tau_N^{-1}e_A(t,x) \tag{7b}$$

$$e_A(t,0) = f_A\left(\lambda_A\,\beta\frac{A(t)}{N-Q(t)}S(t) + \lambda_Y\,\beta\frac{Y(t)}{N-Q(t)}S(t)\right) \tag{7c}$$

$$\begin{aligned}\partial_t e_Y(t,x) + \partial_x e_Y(t,x) &= -\varepsilon(x)\,e_Y(t,x) - \tau_C^{-1}P_e(x)e_Y(t,x) \\ &\quad -\tau_N^{-1}\kappa\big(1-P_e(x)\big)e_Y(t,x)\end{aligned} \tag{7d}$$

$$e_Y(t,0) = f_Y\left(\lambda_A\,\beta\frac{A(t)}{N-Q(t)}S(t) + \lambda_Y\,\beta\frac{Y(t)}{N-Q(t)}S(t)\right) \tag{7e}$$

$$\partial_t a(t,x) + \partial_x a(t,x) = \varepsilon(x)\,e_A(t,x) - r(x)a(t,x) - \tau_N^{-1}\kappa a(t,x) \tag{7f}$$

$$a(t,0) = 0 \tag{7g}$$

$$\begin{aligned}\partial_t y(t,x) + \partial_x y(t,x) &= \varepsilon(x)\,e_Y(t,x) - r(x)y(t,x) - \tau_C^{-1}P_y(x)y(t,x) \\ &\quad -\tau_N^{-1}\kappa\big(1-P_y(x)\big)y(t,x)\end{aligned} \tag{7h}$$

$$y(t,0) = 0 \tag{7i}$$

$$\partial_t q(t,x) + \partial_x q(t,x) = -r(x)q(t,x) + \tau_C^{-1}\Big[P_e(x)e_Y(t,x) + P_y(x)y(t,x)\Big] \tag{7j}$$
$$+\tau_N^{-1}\kappa\Big[e_A(t,x) + a(t,x) + \big(1-P_e(x)\big)e_Y(t,x) + \big(1-P_y(x)\big)y(t,x)\Big]$$

$$q(t,0) = 0 \tag{7k}$$

$$\dot{U}(t) = \int_0^\infty dx\,\Big(r(x)a(t,x) + r(x)y(t,x)\Big) \tag{7l}$$

$$\dot{R}(t) = \int_0^\infty dx\,\Big(r(x)a(t,x) + r(x)y(t,x) + r(x)q(t,x)\Big) \tag{7m}$$

$$E_A(t) = \int_0^\infty dx e_A(t,x), \quad E_Y(t) = \int_0^\infty dx\, e_Y(t,x), \tag{7n}$$
$$A(t) = \int_0^\infty dx\, a(t,x), \quad Y(t) = \int_0^\infty dx\, y(t,x), \quad Q(t) = \int_0^\infty dx\, q(t,x).$$

Parameter	**Name**	**Meaning**
C	Testing capacity	Maximum number of tests able to be administered and processed per day per capita
τ	Testing time	Average amount of time required for an individual be tested (including procrastination, travel time, processing time, etc.) absent of backlogs or delays due to other patients
ρ	Strategy parameter	Fraction of testing capacity devoted to non-clinical testing
η	Concentration parameter	$(1-\eta)$ = Degree to which non-clinical testing resources are utilized on uninfected individuals
κ	Accessibility parameter	Fraction of eligible population open to and compliant with non-clinical testing

Table 1: Testing and quarantine control parameter definitions



Figure 2: Flow diagram for the testing and quarantine control model in Eq. (7). The symptomatic population X_S and fraction κ of the non-symptomatic population X_N transition to the quarantine class Q by clinical and non-clinical testing, respectively, at rates τ_C^{-1} and τ_N^{-1}. Quarantined individuals transition to the recovered class R at age of infection dependent rate $r(x)$. The subset U of the recovered class represents individuals who were previously infected and subsequently recovered without testing and quarantine and are thus unaware that they have obtained immunity.

2.1.4 Transition rates

The transition rates $\varepsilon(x)$ and $r(x)$ are determined by probability distributions for infection ages at which transitions between disease states occur. Specifically, letting $f_\varepsilon(x)$ and denote the probability density for an infected individual to transition from exposed to infectious at infection age x, and letting $f_r(x)$ denote the probability density for an infectious individual transition to recovered at infection age x, the corresponding transition rates are defined as follows:

$$\varepsilon(x) = \frac{f_\varepsilon(x)}{1 - \int_0^x dx'\, f_\varepsilon(x')}, \tag{8}$$

$$r(x) = \frac{f_r(x)}{1 - \int_0^x dx'\, f_r(x)}. \tag{9}$$

These transition rates represent conditional probability densities for an individual to transition to the next disease stage on infection day x given that they are still in the preceding disease stage up to day x. The probability densities for the infectious period duration and total infection duration, denoted $f_{inf}(x)$ and $f_{tot}(x)$, respectively, can be written in terms of $f_\varepsilon(x)$ and $f_r(x)$ as follows:

$$f_{inf}(x) = \int_0^\infty ds\, f_\varepsilon(s) \frac{f_r(x+s)}{1 - \int_0^s ds'\, f_r(s')}, \tag{10}$$

$$f_{tot}(x) = \int_0^x ds\, f_\varepsilon(s) \frac{f_r(x)}{1 - \int_0^s ds'\, f_r(s')}. \tag{11}$$

To clarify, $f_{tot}(x)dx$ represents the probability for an newly infected individual to remain infected for a total duration between x and $x+dx$ days, $f_{inf}(x)dx$ represents the probability for that individual to be infectious (i.e. contagious) for a total duration between x and $x+dx$ days over the course of their infection, and $f_r(x)dx$ represents the probability for that individual to recover between infection days x and $x+dx$ given that they have already entered into an infectious state. If $f_r(x)$ is assumed to be an exponential distribution with mean $1/r$, $r(x)$ reduces to a constant $r(x) = r$ while $f_{inf}(x)$ becomes equivalent to $f_r(x)$. Likewise, if $f_\varepsilon(x)$ is exponential with mean $1/\varepsilon$, $\varepsilon(x)$ reduces to a constant $\varepsilon(x) = \varepsilon$. If both $f_r(x)$ and $f_\varepsilon(x)$ are exponential, $f_{tot}(x)$ becomes a two parameter hypoexponential distribution with parameters ε and r. The exponential distribution assumptions taken together with the correlated symptoms assumption in Sec. 2.1.2 reduce the IPDE testing and quarantine model in Eq. (7) to the ODE testing and quarantine model in (18).

2.2 Distribution and parameter values

2.2.1 COVID-19 variants

The distributions from which the transition rates $\varepsilon(x)$ and $r(x)$ are calculated, as well as the incubation period distribution, are based on epidemiological data for the original, delta, and omicron COVID-19 variants. The incubation period distribution $f_I(x)$ is a widely studied quantity for the early strains of COVID-19 which has been variously fit to log-normal, gamma, or Weilbull distributions (32, 33, 34, 35, 36, 37). The latent period distribution $f_\varepsilon(x)$ and post-infectiousness onset recovery day distribution $f_r(x)$ are comparatively less well studied. For the original COVID-19 strain and delta variant, we utilize the results of Xin et al. (10) and Kang et al. (11), respectively, which estimate both f_ε and f_I to be gamma distributions. We are aware of only one data-based study estimating the incubation period distribution for the omicron variant, Tanaka et al. (38), which fits to a log-normal distribution with median 2.8 days, although other investigations estimating medians but not distributions have likewise obtained results approximately equal to 3 days (39, 40). To maintain consistency with the original and delta variants, we assume f_I for omicron to be gamma distributed with mean and variance comparable to that of (38). We are unaware of any existing estimates for the omicron variant's latent period distribution, so we assume a gamma distribution with mean 1.5 days shorter than that of the incubation period. For all variants, we are unaware of any studies which directly estimate the post-infectiousness onset recovery day distribution $f_r(x)$. However, viral culturing studies have consistently found live viral isolation to cease between 9 and 10 days post-symptom onset (30, 31, 41). We therefore assume a gamma distribution for $f_r(x)$ with mean $\langle f_r \rangle = \langle f_I \rangle + 9.5$ days for each variant, and we assume a scale parameter of 0.25 days to give tight distributions with relatively small interquartile ranges as indicted in (41).

To assess the impact of the PDE elements of our model relative to the corresponding ODE model, we will compare simulation results under exponential and gamma distribution assumptions for f_ε and f_r. Likewise, to assess the impact of pre-symptomatic transmission on disease controllability, we will compare model results between the correlated symptoms and incubation symptoms assumptions in Eq. (4). The means $\langle f_\varepsilon \rangle$ are taken to be equivalent under the exponential and gamma assumptions, while we set $\langle f_r \rangle = \langle f_I \rangle - \langle f_\varepsilon \rangle + 9.5$ days under the exponential assumption as compared to $\langle f_r \rangle = \langle f_I \rangle + 9.5$ days under the gamma assumption. This difference ensures that

the mean infectious period duration $\langle f_{inf} \rangle$ and mean total infection time $\langle f_{tot} \rangle$ are essentially unchanged by the different assumptions on f_r. The means and standard deviations of f_ε, f_r, and f_I, as well as that of the resultant distributions f_{inf} and f_{tot}, are given in Tables 2, 3, and 4 for the original, delta, and omicron COVID variants, respectively. Plots depicting the shapes of f_ε, f_r, and f_I for the three variants are given in Fig. 3. For all variants and distribution assumptions, the average infectious period is approximately 11 days while the average latent period is approximately 1.5 days shorter than the average incubation period, thus indicating an an average 1.5 day pre-symptomatic transmission window under the incubation symptoms assumption. The mean total infection duration decreases from the original to delta to omicron variant.

The remaining model parameters and values are summarized in Table 5. For all COVID variants, the never-symptomatic and eventually-symptomatic population fractions, f_A and f_Y, respectively, are highly uncertain parameters, as estimates based on both modeling and clinical data place f_A anywhere from less than 1% to 90% (12, 13, 14, 15). Further, the value of f_A will depend precisely on our definition of the difference between the moderate to critical symptoms exhibited by the eventually symptomatic class versus the mild to no symptoms exhibited by the never-symptomatic class. Evidence has suggested the majority of COVID cases to be mild (42, 43), so based on these observations, we choose $f_A = 0.75$ and $f_Y = 0.25$. Likewise, the relative values of the never-symptomatic and eventually-symptomatic transmission probabilities, λ_A and λ_Y, respectively, are highly uncertain. Various studies have show that non-symptomatic individuals are as, or less, infectious than symptomatic individuals (13, 14), and that greater symptom severity correlates with higher viral loads (13, 14, 42). Further, a study on the close contacts of index cases has suggested symptomatic individuals to be more infectious than asymptomatic individuals (44). We therefore assume $\lambda_Y = 2\lambda_A$. To determine absolute values, we assume and average contact rate of $\beta = 4$ per day and scale λ_A such that the model's uncontrolled basic reproduction number under the exponential distribution assumptions (i.e. equivalent ODE model), denoted R_0^{un}, matches values taken from the literature (see the Supplementary Section for a derivation and discussion of the basic reproduction number). In other words, we define the following quantity:

$$R_0^{un} = f_A \frac{\beta \lambda_A}{r} + (1 - f_A) \frac{\beta \lambda_Y}{r}, \tag{12}$$

and then choose λ_A such that the above expression matches values for the different COVID variants, where the values of f_A and β are assumed, $1/r$ is equal to $\langle f_{inf} \rangle$ under the exponential distributions assumptions in Tables 2, 3, or 4, and where we assume $\lambda_Y = 2\lambda_A$. Based on estimates of R_0 during the initial phases of the pandemic (45, 46, 47), we set $R_0^{un} = 3.0$ for the original COVID variant. Combining estimates from (11, 48, 49), we set $R_0^{un} = 6.4$ for the delta variant. Based on (49, 50), we set $R_0^{un} = 9.5$ for the omicron variant. We note that changing exponential or gamma distribution assumptions for f_r and f_ε have a negligible impact on actual model basic reproduction number (see supplementary material), so R_0^{un} represents the uncontrolled basic reproduction number for all distribution and symptom onset assumptions.

Original Variant	f_ε Gamma Distribution		f_ε Exponential Distribution	
f_r Gamma Distribution	$\langle f_\varepsilon \rangle = 5.48$	$\sigma_\varepsilon = 2.72$	$\langle f_\varepsilon \rangle = 5.48$	$\sigma_\varepsilon = 5.48$
	$\langle f_r \rangle = 16.38$	$\sigma_r = 2.02$	$\langle f_r \rangle = 16.38$	$\sigma_r = 2.02$
	$\langle f_{inf} \rangle = 10.92$	$\sigma_{inf} = 3.34$	$\langle f_{inf} \rangle = 11.26$	$\sigma_{inf} = 4.81$
	$\langle f_{tot} \rangle = 16.40$	$\sigma_{tot} = 2.02$	$\langle f_{tot} \rangle = 16.74$	$\sigma_{tot} = 2.69$
f_r Exponential Distribution	$\langle f_\varepsilon \rangle = 5.48$	$\sigma_\varepsilon = 2.72$	$\langle f_\varepsilon \rangle = 5.48$	$\sigma_\varepsilon = 5.48$
	$\langle f_r \rangle = 10.90$	$\sigma_r = 10.90$	$\langle f_r \rangle = 10.90$	$\sigma_r = 10.90$
	$\langle f_{inf} \rangle = 10.90$	$\sigma_{inf} = 10.90$	$\langle f_{inf} \rangle = 10.90$	$\sigma_{inf} = 10.90$
	$\langle f_{tot} \rangle = 16.38$	$\sigma_{tot} = 11.23$	$\langle f_{tot} \rangle = 16.38$	$\sigma_{tot} = 12.20$
f_I Gamma Distribution:	$\langle f_I \rangle = 6.88$	$\sigma_I = 3.32$		

Table 2: Original variant distributions based on Refs. (30, 31, 10, 41). Simulations assume either exponential or gamma distributions for f_ε and f_r with means $\langle\ \rangle$ and standard deviations σ as indicated in units of days. Means and standard deviations for the resulting infectious period distribution f_{inf} and total infection duration distribution f_{tot} are likewise indicated. The incubation symptoms assumption utilizes a gamma distributed incubation period length f_I with indicated mean and standard deviation in units of days.

Delta Variant	f_ε Gamma Distribution		f_ε Exponential Distribution	
f_r Gamma Distribution	$\langle f_\varepsilon \rangle = 4.00$ $\langle f_r \rangle = 15.30$ $\langle f_{inf} \rangle = 11.30$ $\langle f_{tot} \rangle = 15.30$	$\sigma_\varepsilon = 2.22$ $\sigma_r = 1.96$ $\sigma_{inf} = 2.94$ $\sigma_{tot} = 1.96$	$\langle f_\varepsilon \rangle = 4.00$ $\langle f_r \rangle = 15.30$ $\langle f_{inf} \rangle = 11.43$ $\langle f_{tot} \rangle = 15.43$	$\sigma_\varepsilon = 4.00$ $\sigma_r = 1.96$ $\sigma_{inf} = 4.02$ $\sigma_{tot} = 2.14$
f_r Exponential Distribution	$\langle f_\varepsilon \rangle = 4.00$ $\langle f_r \rangle = 11.30$ $\langle f_{inf} \rangle = 11.30$ $\langle f_{tot} \rangle = 15.30$	$\sigma_\varepsilon = 2.22$ $\sigma_r = 11.30$ $\sigma_{inf} = 11.30$ $\sigma_{tot} = 11.51$	$\langle f_\varepsilon \rangle = 4.00$ $\langle f_r \rangle = 11.30$ $\langle f_{inf} \rangle = 11.30$ $\langle f_{tot} \rangle = 15.30$	$\sigma_\varepsilon = 4.00$ $\sigma_r = 11.30$ $\sigma_{inf} = 11.30$ $\sigma_{tot} = 11.99$
f_I Gamma Distribution: $\langle f_I \rangle = 5.80$ $\sigma_I = 3.02$				

Table 3: Delta variant distributions based on Refs. (30, 31, 11, 41). Meanings of quantities are as described in Table 2.

Omicron Variant	f_ε Gamma Distribution		f_ε Exponential Distribution	
f_r Gamma Distribution	$\langle f_\varepsilon \rangle = 1.50$ $\langle f_r \rangle = 12.50$ $\langle f_{inf} \rangle = 11.00$ $\langle f_{tot} \rangle = 12.50$	$\sigma_\varepsilon = 1.00$ $\sigma_r = 1.77$ $\sigma_{inf} = 2.03$ $\sigma_{tot} = 1.77$	$\langle f_\varepsilon \rangle = 1.50$ $\langle f_r \rangle = 12.50$ $\langle f_{inf} \rangle = 11.00$ $\langle f_{tot} \rangle = 12.50$	$\sigma_\varepsilon = 1.50$ $\sigma_r = 1.77$ $\sigma_{inf} = 2.31$ $\sigma_{tot} = 1.77$
f_r Exponential Distribution	$\langle f_\varepsilon \rangle = 1.50$ $\langle f_r \rangle = 11.00$ $\langle f_{inf} \rangle = 11.00$ $\langle f_{tot} \rangle = 12.50$	$\sigma_\varepsilon = 1.00$ $\sigma_r = 11.00$ $\sigma_{inf} = 11.00$ $\sigma_{tot} = 11.04$	$\langle f_\varepsilon \rangle = 1.50$ $\langle f_r \rangle = 11.00$ $\langle f_{inf} \rangle = 11.00$ $\langle f_{tot} \rangle = 12.50$	$\sigma_\varepsilon = 1.50$ $\sigma_r = 11.00$ $\sigma_{inf} = 11.00$ $\sigma_{tot} = 11.10$
f_I Gamma Distribution: $\langle f_I \rangle = 3.00$ $\sigma_I = 1.22$				

Table 4: Omicron variant distributions based on Refs. (30, 31, 38, 41). Meanings of quantities are as described in Table 2



Figure 3: Latent period distributions $f_\varepsilon(x)$, incubation period distributions $f_I(x)$, and post-infectiousness onset recovery day distributions $f_r(x)$ as functions of the age of infection x for the original, delta, and omicron variants of COVID-19. Model simulations will consider combinations of exponential (dotted lines) and gamma (solid lines) distribution assumptions for f_ε and f_r, as well as an incubation period symptom onset assumption using a gamma distribution for f_I or a correlated symptom assumption where symptom onset coincides exactly with the onset of infectiousness.

2.2.2 Generic diseases

In addition to the COVID-19 variants, we consider a generic disease similar to the original variant but with a variable offset between the mean incubation and latent period. Defining $z = \langle f_I \rangle - \langle f_\varepsilon \rangle$, we consider both positive and negative z values. Positive z values represent diseases for which symptom onset typically occurs after infectiousness onset, thus allowing for significant levels of pre-symptomatic transmission as occurs, for example, with the viruses SARS-CoV-2 and 2009 pandemic influenza H1N1 (51, 52, 28). Negative z values indicate viruses like SARS-CoV and MERS-CoV for which symptom onset typically occurs well before infectiousness onset or peak infectivity, thus making pre-symptomatic transmission insignificant or absent entirely (28, 29). In all cases, we assume fixed gamma distributions for f_ε and f_r similar to those of the original COVID-19 variant and vary z by considering different gamma distributed incubation periods f_I. Assumed means and standard deviations for f_ε, f_r, and f_I for the specific z values under consideration are given in Table 6, and the distributions are pictured graphically in Fig. 4. Remaining model parameters are taken to be equivalent to those of COVID-19 in Table 5, where we will consider a variety of R_0^{un} and corresponding λ_A values.

Parameter	Name	Meaning	Value	Refs
R_0^{un}	Uncontrolled basic reproduction number	Model R_0 with no testing or quarantine control	3.0 (Original Variant) 6.4 (Delta Variant) 9.5 (Omicron Variant)	(11, 45, 46, 47, 48, 49, 50)
β	Contact rate	Average number of contacts per individual per unit time	4.0 $(\text{day})^{-1}$	Assumed
λ_A	Never-symptomatic transmission probability	Probability of disease transmission per susceptible-never symptomatic contact	0.055 (Original Variant) 0.113 (Delta Variant) 0.173 (Omicron Variant)	Inferred from R_0^{un}
λ_Y	Eventually-symptomatic transmission probability	Probability of disease transmission per susceptible-eventually symptomatic contact	$2\lambda_A$	(13, 14, 42, 44)
f_A	Asymptomatic fraction	Fraction of infections which remain mild or asymptomatic	0.75	(12, 13, 14, 15, 42, 43)
f_Y	Symptomatic fraction	Fraction of infections which become severe and symptomatic	$1 - f_A$	-
N	Population size	Total number of hosts (assumed fixed)	50000	Assumed

Table 5: Model parameter definitions and numerical values used for COVID-19 variants.

Offset	$z = -4.5$	$z = -3.0$	$z = -1.5$	$z = 0$	$z = 1.5$	$z = 3.0$	$z = 4.5$
$\langle f_I \rangle$	1.50	3.00	4.50	6.00	7.50	9.00	10.50
σ_I	1.22	1.91	2.27	2.83	2.83	2.83	2.83
$\langle f_\varepsilon \rangle = 6.00$, $\sigma_\varepsilon = 2.83$ $\langle f_r \rangle = 17.00$, $\sigma_r = 2.06$ $\langle f_{inf} \rangle = 11.02$, $\sigma_{inf} = 3.45$ $\langle f_{tot} \rangle = 17.02$, $\sigma_{tot} = 2.06$							

Table 6: Gamma distribution parameters for generic diseases with different offsets between mean incubation and latent periods denoted by $z = \langle f_I \rangle - \langle f_\varepsilon \rangle$. Means $\langle\ \rangle$, standard deviations σ, and z values are given in units of days.



Figure 4: Latent period distribution $f_\varepsilon(x)$, incubation period distributions $f_I(x)$, and post-infectiousness onset recovery day distribution $f_r(x)$ as functions of the age of infection x for generic diseases with different offsets z between mean incubation and latent periods indicated in units of days.

2.3 Numerical integration and optimization

We compute the discretized dynamical equations for the system (7) using the upwind scheme for non-linear partial integro-differential equations with integral boundary conditions detailed in Ref. (53), and then use the midpoint method to integrate the system forward in time. We assume initial infection conditions $e_A(0,x)\Delta x = f_A$ and $e_Y(0,x)\Delta x = f_Y$ for $x \in [0, \Delta x]$, where $\Delta x = 1/6$ days is the discretization length for the age of infection domain, and $e_A(0,x) = e_A(0,y) = 0$ for $x > \Delta x$. The system is assumed otherwise to be initially completely susceptible such that $S(0) = N - 1$ and $a(0,x) = y(0,x) = q(0,x) = R(0) = U(0) = 0$ for all x. Age of infection integrals are computed using the trapezoid rule where we assume a finite domain with an upper bound $x_{max} = 80$ days (the number of infected individuals who would otherwise recover after x_{max} is negligible for all disease variants considered). We integrate the model equations from an initial time $t_0 = 0$ to final time $t_f = 2$ years using a time step $\Delta t = 1/10$ days. When implementing testing and quarantine control, we find optimal allocation strategies ρ for reducing the total infection size $S(t_0) - S(t_f)$ under a variety C, η, and κ values using the *fmincon* function in *Matlab R2021b*.

3 Results

3.1 Optimal total infection size reduction and disease controllability

Figures 6 and 7 display total infection sizes under optimal resource allocation strategies as a function of testing capacity for the different COVID variants as well as the generic disease with z and R_0^{un} comparable to that of delta and omicron variants ($z = 1.5$ days and $R_0^{un} = 6.4$ or 9.5). Curve color and dashing pattern represent different combinations of assumptions regarding symptom onset (incubation symptoms or correlated symptoms) and distributions for f_ε and f_r (gamma or exponential) as detailed by the legend in Fig. 5. Different plots represent different disease variants and different choices for η and κ values. The presented results focus on two cases in particular: "random testing" ($\kappa = 1.00, \eta = 0$) and "realistic testing" ($\kappa = 0.85, \eta = 0.75$). Random testing represents a population-wide pure random sampling non-clinical testing program, while realistic testing a represents non-clinical testing scenario more likely to be encountered in the real world, where contact tracing and natural biases result in increased testing of infected individuals but

where some of the population is inaccessible or resistant to testing efforts. The case of no control is represented at zero testing capacity ($C = 0$). By definition, symptom onset assumptions and testing parameter values have no influence on model outcomes at $C = 0$, but interestingly, we see that exponential versus gamma distribution assumptions for f_ε and f_r have no meaningful impact on total infection size at $C = 0$ even though model dynamics differ.

Generally, as the testing capacity C increases, Figs. 6 and 7 show that the total infection size decreases when resources are distributed optimally. In particular, complete disease eradication is possible at reasonably achievable testing capacities for a weaker variant when non-clinical testing can be effectively targeted at individuals who are actually infected (large η in Figs. 6b and 6d). However, if non-clinical testing does not target infected individuals (small η in Figs. 6a and 6c), or if the variant is stronger (Fig. 7), eradication may not be achievable at the reduced testing capacities available during the initial phases of a novel disease outbreak. The accessibility κ has a smaller influence on reducing total infections compared to the concentration η, and disease eradication may possible even for smaller accessibility levels (Fig. 6d). This result emphasizes the importance of implementing effective contact tracing programs for COVID-like diseases even if such programs can only reach a relatively small number of individuals.

Together, Figs. 6 and 7 exemplify the influences of symptom onset assumptions, period distribution assumptions, testing parameter values, and disease variant characteristics on disease controllability. By controllability, we specifically mean the amount of testing capacity required to achieve a given reduction in total infection size. We consider a set 'A' of assumptions and parameters to be less controllable than another set 'B' if set 'A' requires a larger testing capacity to reduce total infection size to half, for example, of the uncontrolled value under optimal resource allocation strategies (see supplementary material for alternative but equivalent measures of controllability involving the basic reproduction number).

Gamma versus exponential distribution assumptions for f_r have a profound effect on controllability. Comparing a dashed curve (exponential) to a solid curve (gamma) of the same color in either Fig. 6a, 6b, or 7 shows that the gamma assumption produces a large decrease in controllability relative to the exponential assumption. On the other hand, the gamma assumption for f_ε increases controllability relative to the exponential assumption. This is seen in Fig. 6a, 6b, or 7 by comparing a solid orange curve to a solid blue curve or a solid purple curve to a solid gold curve, and likewise

for dashed curves. The effects of incubation symptom versus correlated symptom assumptions are exemplified by comparing a solid gold to solid blue curve or solid purple to solid orange curve, and likewise for dashed curves. Here, incubation symptom assumptions decrease controllability relative to correlated symptom assumptions. Interestingly, for a given assumption on f_r, the decrease in controllability due to incubation symptoms is nullified to some extent by the increase in controllability due to a gamma distributed f_ε such that solid(dashed) blue and purple curves can lie close to one another bounded by solid(dashed) red and gold curves. In other words, the IPDE specific assumptions for latent period length and symptom onset tend to counteract one another. The full IPDE model (solid purple curve) generally shows a significant reduction in controllability relative to the full ODE model (dashed blue curve).

The influences of the testing parameters η and κ on controllability are shown in Figs. 6c and 6d, where smaller values tend to decrease controllability. The influences of disease variant characteristics are seen by comparing Fig. 6b to the corresponding curves in all plots in Fig. 7. Here, the omicron COVID variant is significantly less controllable than the delta variant, and the delta variant is moderately less controllable than the original variant. These controllability reductions may be caused by either increases in transmissibility or decreases in the mean latent period length associated with each COVID variant, where $R_0^{un} = 3.0, 6.4$, and 9.5 and $\langle f_\varepsilon \rangle = 5.48, 4.00$, and 1.50 days for the original, delta, and omicron variants, respectively (the mean incubation-latent offsets z and mean infectious period lengths are approximately equal for all variants). The independent influences of transmissibility and latent period length can be deduced using the generic disease in Figs. 7c and 7d. Here, the mean latent period $\langle f_\varepsilon \rangle = 6.00$ days is comparable to that of the original variant, and comparing Fig. 6b to Figs. 7c and 7d thus shows that increases in transmissibility alone cause decreases in controllability. Likewise, comparing Fig. 7a and 7b to Fig. 7c and Fig. 7d, respectively, shows that decreases in $\langle f_\varepsilon \rangle$ alone cause decreases in controllability. A summary of all observed controllability reducing factors is given in Table 7.

Controllability reducing factors
f_r gamma distribution
f_ε exponential distribution
reduction in non-clinical concentration η
reduction in non-clinical accessibility κ
increase in overall transmissibility (i.e. R_0^{un})
reduction in mean latent period $\langle f_\varepsilon \rangle$
incubation symptoms

Table 7: List of controllability reducing factors observed in Figs. 6 and 7



Figure 5: Legend for interpreting curve color and style in Figs. 6, 7, 8, 9, and 10. Different colors represent different combinations of exponential and gamma distribution assumptions for f_ε along with different assumptions for correlated versus incubation symptom onset as indicated by the colored table. Dashed lines indicate the exponential distribution assumption for f_r while solid lines indicate the gamma distribution assumption. The model with all IPDE elements is given by a solid purple curve while the ODE equivalent model is given by a dashed blue curve.



(a) Original Variant: Variable Distribution and Symptom Assumptions



(b) Original Variant: Variable Distribution and Symptom Assumptions



(c) Original Variant: Gamma Distribution and Incubation Symptom Assumptions



(d) Original Variant: Gamma Distribution and Incubation Symptom Assumptions

Figure 6: Total infection sizes under optimal allocation strategies as a function of testing capacity for the original COVID variant under a variety of symptom onset, period distribution, and testing parameter assumptions. The meaning of curve color and dashed versus solid curves is given in Fig. 5. Note the changes in x-axis scale for each plot.

3.2 Optimal allocation strategies

Figures 8 and 9 show the optimal resource allocation strategies ρ as a function of testing capacity C corresponding to the total infection size reductions in Figs. 6 and 7. Curve colors and styles are interpreted analogously according to the legend in Fig. 5. The value $\rho = 0$ represents a clinical-testing only strategy while $\rho = 1$ represents a non-clinical testing only strategy, with intermediate values represent mixed clinical and non-clinical testing strategies. In all cases, we find that optimal strategies call for clinical testing only at low testing capacities up to some strategy threshold capacity C^{th}, beyond which optimal strategies become mixed. As testing capacity increases further beyond C^{th}, optimal strategies call for greater and greater shares of resources to be devoted to non-clinical testing.

The insets in each plot (except Fig. 8d) zoom in on C^{th} values for the various distribution, symptom, testing parameter, and disease parameter assumptions. Figures 8 and 9 show that all of these factors except the non-clinical accessibility κ are important in determining C^{th}, while Fig. 8d indicates that C^{th} is in fact independent of κ. This observation can be explained from our model equations, where the total rate of flow of infected individuals to the quarantine class due to non-clinical testing is given by $\tau_N^{-1}\kappa X_N(t)$. At the threshold C^{th}, the optimal fraction of resources ρ devoted to nonclinical testing is only infinitesimally larger than zero, and Eq. (5) implies $\tau_N^{-1}\kappa X_N(t) \approx \rho C N X_N(t)/\Big(X_N(t)+(1-\eta)(S(t)+U(t))\Big)$ for very small ρ. We thus conclude that the rate at which individuals are quarantined by optimally allocated non-clinical testing is independent of κ at testing capacities near C^{th}, and that κ effectively vanishes from the model equations under optimal strategies at C^{th}.



(a) Delta Variant: Variable Distribution and Symptom Assumptions



(b) Omicron Variant: Variable Distribution and Symptom Assumptions



(c) Generic Disease $R_0^{un} = 6.4$, $z = 1.5$ days: Variable Distribution and Symptom Assumptions



(d) Generic Disease $R_0^{un} = 9.5$, $z = 1.5$ days: Variable Distribution and Symptom Assumptions

Figure 7: Total infection sizes under optimal allocation strategies as a function of testing capacity for the delta and omicron COVID variants, as well a generic disease similar to COVID-19, under a variety of symptom onset, period distribution, and testing parameter assumptions. The meaning of curve color and dashed versus solid curves is given in Fig. 5. The generic disease assumes R_0^{un} values equal to those of the delta and omicron COVID variants with a mean latent period $\langle f_\varepsilon \rangle = 6.00$ days comparable to that of the original variant, and assumes a incubation-latent offset $z = 1.5$ days similar to all COVID variants. Note the changes in x-axis scale for each plot.



(a) Original Variant: Variable Distribution and Symptom Assumptions



(b) Original Variant: Variable Distribution and Symptom Assumptions



(c) Original Variant: Gamma Distribution and Incubation Symptom Assumptions



(d) Original Variant: Gamma Distribution and Incubation Symptom Assumptions

Figure 8: Optimal resource allocation strategies for the original COVID variant corresponding to the total infection sizes in Fig. 6. The value $\rho = 0$ corresponds to clinical-testing only strategy, $\rho = 1$ corresponds to non-clinical testing only, with intermediate values representing mixed strategies. Insets within plots (aside from Fig. 8d) highlight strategy threshold testing capacity values C^{th} where strategies switch from clinical only to mixed. Note the changes in x-axis scale for each plot.



(a) Delta Variant: Variable Distribution and Symptom Assumptions



(b) Omicron Variant: Variable Distribution and Symptom Assumptions



(c) Generic Disease $R_0^{un} = 6.4$, $z = 1.5$ days: Variable Distribution and Symptom Assumptions



(d) Generic Disease $R_0^{un} = 9.5$, $z = 1.5$ days: Variable Distribution and Symptom Assumptions

Figure 9: Optimal resource allocation strategies for the delta and omicron COVID variants as well as comparable generic diseases with a longer mean incubation period $\langle f_\varepsilon \rangle = 6.0$ days. Optimal strategies correspond to the optimal total infection sizes in Fig. 7. The value $\rho = 0$ corresponds to clinical-testing only strategy, $\rho = 1$ corresponds to non-clinical testing only, with intermediate values representing mixed strategies. Insets within plots highlight strategy threshold testing capacity values C^{th} where strategies switch from clinical only to mixed. Note the changes in x-axis scale for each plot.

3.3 Controllability and the role of non-clinical testing

Figures 6, 7, 8, and 9 together depict the relationship between controllability and the role of non-clinical testing in optimal strategies. We say that the role of non-clinical testing is increased for set 'A' of distribution, symptom onset, testing parameter, and disease parameter assumptions relative to another set 'B' if the optimal ρ value at a given testing capacity for set 'A' is larger. Applying the same comparative analyses to Figs. 8 and 9 as was done for Figs. 6 and 7 in Sec. 3.1, we find that, except for incubation symptoms assumption, all factors that reduce controllability in Table 7 coincide with the factors that reduce the role of non-clinical testing. There thus exists a strong relationship between controllability influencing factors and the role of non-clinical testing in optimal strategies.

The relationship between non-clinical testing and symptom onset assumptions is more nuanced than for the other controllability reducing factors. Understanding this relationship is important for disease control, as symptom onset assumptions either incorporate (incubation symptoms) or disregard (correlated symptoms) the capacity for presymptomatic transmission associated with the incubation-latent period offset for COVID-19. In some cases (compare gold to blue or purple to orange curves in Figs. 8a and 8b), incubation symptoms decrease the role of non-clinical testing relative to correlated symptoms, thus following the pattern of controllability reducing factors coinciding with non-clinical testing reducing factors. In other cases (Fig. 9), incubation symptoms increases the role of non-clinical testing for a large range of testing capacities above the strategy thresholds C^{th} even though controllability is reduced. Of further complication, in these cases, there exist smaller ranges of larger testing capacities where the role of non-clinical testing is increased by the incubation symptoms assumption.

We utilize strategy testing capacity thresholds C^{th} to analyze the relationship between non-clinical testing and symptom onset assumptions. Specifically, in Figs. 8a and 8b, the reduced roles of non-clinical testing under the incubation symptom assumptions correspond to larger C^{th} values in comparison to the correlated symptoms assumptions. Likewise, in Fig. 9, the enhanced roles of non-clinical testing over large ranges of testing capacities correspond to smaller C^{th} for incubation symptoms in comparison to correlated symptoms. Thus, increases and decreases in C^{th} due to symptom onset assumptions are simple indicators of decreases and increases, respectively, in the

roles of non-clinical testing. To further simplify our analysis, we restrict our attention to the most realistic model assumptions using gamma distributions for f_ε and f_r in order to compare incubation symptoms (solid purple curves) to correlated symptoms (solid orange curves).

Numerically calculating C^{th} values for a spectrum of η values, we plot the results as curves in the (C, η) plane, where different curves represent different variant and symptom onset assumptions (Fig. 10). For a given variant, if the correlated symptom curve (orange) falls to the left of the incubation symptom (purple) curve at a given η, then C^{th} is larger for incubation symptoms, thus implying that incubation symptoms reduce the role of non-clinical testing. Conversely, if the correlated symptom curve falls to the right of the incubation symptoms curve, incubation symptoms enhance the role of non-clinical testing. Further, for each variant, there exists a threshold concentration η^{th} (indicated by black circles in Fig. 10), above which the role of non-clinical testing is always enhanced, and below which it is always reduced, where threshold values decrease as variant strength increases. Thus, whether or not the presence of presymptomatic transmission warrants allocation of additional resources to non-clinical testing than would otherwise be optimal depends on both variant strength and the precision to which non-clinical tests can locate infected individuals: stronger variants require less precision in order to justify additional resources for non-clinical testing.

Figure 10 is of additional value as a practical result for disease management officials when determining whether or not complicated resource allocation decisions need be considered. Supposing that the available testing capacity C and an estimate for the concentration η of a non-clinical testing program are known, if the corresponding (C, η) value falls to the left of or below a variant curve in Fig. 10, the optimal strategy for that variant is clinical testing only, and officials need not consider difficult choices in allocating resources. Otherwise, if the (C, η) value falls to the right of or above a variant curve, the optimal strategy is mixed clinical and non-clinical testing, and officials know that critical decisions must be made in order to ensure that resources are properly allocated.



Figure 10: Strategy threshold testing capacities at various concentration levels η for the different COVID variants. Curves represent (C, η) values where the strategy threshold capacity C^{th} occurs, assuming either incubation symptoms (purple) or correlated symptoms (orange) with gamma distributed f_r and f_ε. At (C, η) points above or to the right of a given curve, optimal strategies are mixed clinical and non-clinical for that variant and symptom assumption. At points below or to the left, optimal strategies are clinical only. Circles indicate points where C^{th} is equivalent for both symptom assumptions. At η values above a circle, incubation symptoms increases the role of non-clinical testing in optimal strategies for the corresponding variant. At η values below a circle, incubation symptoms reduce the role of non-clinical testing.

3.4 Variable incubation-latent offsets

In Fig. 11, we plot optimal total infection sizes and corresponding optimal resource allocation strategies for the generic disease with $R_0^{un} = 3.0$ under a variety of incubation-latent offsets z. Here, we consider only gamma distributions for f_r and f_ε, and we consider both incubation and correlated symptom assumptions (the offset z is irrelevant under correlated symptoms). The offset z is found to have a strong influence on controllability (Figs. 11a and 11b); as z increases from negative to positive values, controllability decreases significantly. Thus, diseases for which symptom onset typically occurs before peak infectiousness are more easily controlled with symptom-based interventions compared to diseases for which symptom onset typically occurs after infectiousness onset (i.e. presymptomatic transmission). Further, relative to the correlated symptoms assumption, incubation symptoms are more controllable for $z < 0$ and less controllable for $z > 0$ (Figs. 11a and 11b). This finding agrees with the notion that diseases for which symptoms precede significant infectiousness are easier to control; if a model disregards the offset between symptom and infectiousness onset, it will underestimate controllability for diseases with $z < 0$ and overestimate controllability for diseases with $z > 0$. Thus, Table 1 should be modified to state that incubation symptoms are a controllability reducing factor only for diseases with $z > 0$, while correlated symptoms are a controllability reducing factor for $z < 0$. For the case $z = 0$, controllability under incubation symptoms is close to (but not exactly equal to) controllability under correlated symptoms (Figs. 11a and 11b). Apparently, when symptom and infectiousness onset occur together only on average rather than always together, controllability is very slightly reduced.

As a function of testing capacity, optimal strategies for all z behave qualitatively similar to those of the COVID-19 variants; optimal strategies are clinical-only at low testing capacities and become mixed clinical and non-clinical beyond a threshold capacity C^{th} (Figs. 11c and 11d). As with the COVID-19 variants, the relationships between symptom onset assumptions, controllability, and optimal allocation strategies are complicated for the generic disease. For random testing (Fig. 11c), the role of non-clinical testing decreases (as measured by increases in C^{th}) as z increases for $z \in [-4.5, 1.5]$, thus following the trend of controllability reducing factors coinciding with non-clinical testing reducing factors. However, the role of non-clinical testing increases for $z = 4.5$ days relative to $z = 1.5$ days even though controllability decreases. For realistic testing (Fig. 11d),

the role of non-clinical testing decreases progressively for $z \in [-4.5, 0]$, after which it progressively increases. Of further complication, for larger R_0^{un} values (see supplementary material), the role of non-clinical testing can increase progressively as z increases despite the progressive decrease in controllability.

The role of non-clinical testing for incubation symptoms relative to that of correlated symptoms displays distinct behavior for $z < 0$ and $z \geq 0$. Specifically, for $z = -1.5$ days (green curve in Figs. 11c and 11d), the role of non-clinical testing is enhanced relative to correlated symptoms at $\eta = 0$, but is reduced at $\eta = 0.85$. This behavior is counterintuitive; one would expect that if non-clinical testing is effective enough at low η to have an enhanced role in optimal strategies, then it would also have an enhanced role at larger η, as increasing η would increase its efficacy further. This is indeed the case for the COVID-19 variants that have a positive z approximately equal to 1.50 days (Fig. 10). For these variants, the role of non-clinical testing becomes enhanced relative to correlated symptoms at some threshold concentration η^{th}, and then remains enhanced for all $\eta > \eta^{th}$. Figure 12 presents the analog to Fig. 10 for the generic disease for $R_0^{un} = 3.0$ (see supplementary material for $R_0^{un} = 6.4$ and $R_0^{un} = 9.5$). Here, we numerically calculate the strategy threshold capacities C^{th} for a spectrum of η values for each z offset and the correlated symptoms assumptions, and then plot the results as curves in the (C, η) plane. For each z curve, there is a threshold concentration η^{th} where a crossing with the correlated symptoms curve occurs. $z \geq 0$ curves are to the right of the correlated symptoms curve for $\eta < \eta^{th}$ (indicating diminished non-clinical testing roles) and to the left for $\eta > \eta^{th}$ (indicating enhanced non-clinical testing roles). However, $z < 0$ curves are to the left of the correlated symptoms curve for $\eta < \eta^{th}$ (indicating enhanced non-clinical testing roles) and to the right for $\eta > \eta^{th}$ (indicating diminished non-clinical testing roles). We thus find major qualitative differences between $z > 0$ diseases (i.e. those with presymptomatic transmission) and $z < 0$ diseases (i.e those with preinfectiousness symptom onset) in regards to the influence of realistic incubation and latent periods on optimal resource allocation strategies relative to simpler models.

From Figs. 10 and 12 (as well as the corresponding plots in the supplementary material), it is clear that threshold concentrations η^{th} depend on both the incubation-latent offset z and the overall transmissibility as measured by R_0^{un}, and may also depend on the mean latent period length. To visualize these influences, we find the thresholds η^{th} numerically for the $z \leq 0$ diseases as well

as the COVID-19 variants, assuming a spectrum of R_0^{un} values for each model by changing the overall transmissibility. The results are plotted in Fig. 13 as curves in the (R_0^{un}, η) plane, where each curve represents η^{th} values for a different set of gamma distributed latent and incubation periods taken from Tables 2, 3, 4, and 6, assuming gamma distributions for f_r. If a disease management official is designing a testing resource allocation strategy to control a disease for which they know the basic reproduction number and an estimate for their testing program's η reproduction, they can locate the corresponding point in Fig. 13. If their point falls above the relevant incubation/latent period assumption curve, then due to presymptomatic transmission, optimal strategies will call for an increase in non-clinical testing resources relative to a comparable simpler disease for which infectiousness and symptoms always coincide. If their point falls below the relevant incubation/latent period assumption curve, optimal strategies will call for a reduction in non-clinical testing relative to a comparable simpler disease despite the presence of presymptomatic transmission. Generally, smaller R_0^{un} values require greater η in order to justify allocating extra resources to non-clinical testing, thus corroborating our previous observation that stronger diseases require less precise non-clinical testing programs (i.e smaller η) in order to justify allocating additional resources to non-clinical testing due to presymptomatic transmission. We see further that larger z diseases and diseases with shorter latent periods (compare the omicron curve to the $z = 1.50$ curve) likewise require less precision in order to justify increasing resources to non-clinical testing. In other words, the factors of larger R_0^{un}, larger z, and smaller latent period expand the parameter space for which non-clinical testing is enhanced in optimal strategies due to presymptomatic transmission. Note that as R_0^{un} falls below 2.0, enhanced non-clinical testing is never justified. Thus, sufficiently weak diseases do not warrant additional non-clinical testing resources, even if presymptomatic transmission may be significant.



(a) Generic Disease $R_0^{un} = 3.0$: Gamma Distribution Assumptions and Variable Incubation-Latent Offsets



(b) Generic Disease $R_0^{un} = 3.0$: Gamma Distribution Assumptions and Variable Incubation-Latent Offsets



(c) Generic Disease $R_0^{un} = 3.0$: Gamma Distribution Assumptions and Variable Incubation-Latent Offsets



(d) Generic Disease $R_0^{un} = 3.0$: Gamma Distribution Assumptions and Variable Incubation-Latent Offsets

Figure 11: Optimal total infection sizes and corresponding optimal resource allocation strategies for the generic disease with $R_0^{un} = 3.0$, assuming gamma distributions for f_ε and f_r. Curve colors represent different offsets $z = \langle f_I \rangle - \langle f_\varepsilon \rangle$ between mean incubation and latent periods as indicated by the legend in Fig. 11a (measured in units of days). Black dashed curves represent the correlated symptoms assumption where z values are irrelevant. Insets in Figs. 11c and 11d zoom in on strategy threshold testing capacities C^{th} where optimal strategies switch from clinical only to mixed clinical and non-clinical.



Figure 12: Strategy threshold testing capacities at various concentration levels η for the generic disease with $R_0^{un} = 3.0$. Curves represent (C, η) values where the strategy threshold capacity C^{th} occurs, assuming either incubation symptoms (colored curves) or correlated symptoms (black dashed curve) with gamma distributed f_r and f_ε. Colors represents different off sets z between the mean incubation and mean latent period, with values in the legend given in units of days. At (C, η) points above or to the right of a given curve, optimal strategies are mixed clinical and non-clinical for that z value or symptom assumption. At points below or to the left, optimal strategies are clinical only. The η value for which a colored curve crosses the black curve represents a threshold η^{th} for which the role of non-clinical testing switches between enhanced and diminished compared to the correlated symptoms assumption.



Figure 13: Curves depicting threshold concentrations η^{th} as a function of the uncontrolled basic reproduction number for gamma distributed latent and incubation period associated with the COVID-19 variants and our generic diseases, where f_r is assumed to be gamma distributed. Each curve represents a different latent/incubation period set that has a particular incubation-latent offset z denoted in the legend in units of days. The legend specifies the COVID variants along with their z offsets, and the generic disease indicated by only their z offsets. The actual R_0^{un} values for the COVID variants are indicated by makers on the plot. Points above a given curve represent the parameter space over which presymptomatic transmission justifies increasing resources to non-clinical testing for a disease with the corresponding latent and incubation periods. For points below a curve, presymptomatic transmission does not justify increasing non-clinical testing resources in optimal strategies.

4 Discussion

4.1 Curbing epidemics under resource limitations

The results of our work largely corroborate the optimality of the testing strategies adopted by real-world disease management planners during the early phases of the COVID-19 pandemic. Namely, when testing resources are in short supply, they should be reserved for the most symptomatic and critically ill patients (6, 7, 8). Although these policies may have been adopted in order to prevent mortality, we have found that they are also good policies for suppressing the epidemic. More generally, our work shows that such policies are optimal for a broad range of disease characteristics and non-clinical testing program characteristics. Diseases with longer or shorter latent periods, stronger or weaker transmissibility, presymptomatic transmission or preinfectiousness symptom onset or correlated symptom-infectiousness onset, and exponential or gamma period distributions all call for qualitatively similar polices as a function of testing capacity; optimal protocols call for clinical-only testing at testing capacities below a threshold C^{th}, and call for mixed clinical and non-clinical strategies at greater testing capacities. Interestingly, in a previous work (18) where we analyzed optimally reducing the epidemic peak height (rather than total infection size) using the ODE of our model here, we observed the same threshold behavior separating testing capacity regions between optimal clinical-only and mixed strategies. Thus, the threshold behavior appears to be a general feature of optimal allocation strategies under limited testing resources.

Figures 6, 7, and 11 depicting optimal total infection size for "realistic" and "random" non-clinical testing programs illuminate the feasibility or infeasibility of curbing a novel disease outbreak with a testing a quarantine program. Random testing ($\eta = 0$) is unlikely to be successful at the low testing capacities expected at the initial stages of an novel disease outbreak as production of newly developed tests falls well behind demand, even if the entire population is accessible and amenable to the limited number of tests available ($\kappa = 1$). However, significant disease suppression is possible at larger concentrations η even if the overall accessibility κ is small. This result stresses the importance of early implementation of effective contact tracing and public outreach programs encouraging individuals with suspected or probable recent transmission to seek testing, even if significant portions of the population are not open or accessible to such efforts. Importantly, this conclusion holds for the spectrum of model assumptions and disease characteristics analyzed in this

paper.

4.2 Influence of model assumptions on controllability

Throughout this work, we have identified a number of disease characteristics and model assumptions that influence predictions of controllability. Model assumptions are critically important, as we have found that the equivalent ODE model can severely overestimate controllability relative to the more realistic full IPDE model. A major contributing factor to this effect is the gamma period distribution assumption for f_r in the IPDE model. This observation accords with previous models with identification + isolation/quarantine controls, where it was observed that an exponentially distributed infectious period can significantly overestimate controllability relative to a gamma distribution (27). In essence, quarantining is more effective under the exponential assumption due to its ability to significantly reduce the infectious period length of individuals in the long tail of the distribution (see Fig. 3). Likewise, under the exponential assumption, significantly larger numbers individuals recover naturally within the first few days of infectiousness onset in comparison to the gamma assumption, so delays in testing due to low capacity are irrelevant in these cases and are thus less detrimental to controllability. Conversely, for the latent period distribution, a gamma distribution assumption increases controllability relative to the exponential assumption (although to a lesser degree than that with which a gamma f_r reduces controllability) for reasons analogous to those of infectious period. Namely, under the exponential assumption, much larger numbers of individuals rapidly transition from exposed to infectious in comparison to the gamma distribution, so there is less time to locate and remove new infections before they begin generating new transmissions, and delays in identifying and quarantining infections due to supply limitations are thus more detrimental. On a more basic level, although gamma distributions for f_ε and f_r have no noticeable effect on total infection size under no control, they flatten/delay and sharpen/accelerate the uncontrolled epidemic peak, respectively, as compared to exponential distributions (see the supplementary material). Intuitively, a disease that peaks earlier and to a greater degree on its on volition will be more difficult to control.

Symptom onset assumptions based on the age-of-infection can reduce or increase controllability depending on the incubation-latent offset z, as controllability generally decreases as z increases. Under correlated symptoms, active spreaders in the eventually symptomatic class always show

symptoms and are thus always targeted with efficacious clinical testing. Under incubation symptoms, however, positive z values imply presymptomatic transmissions, meaning that some of the active spreaders can only be targeted with non-clinical testing which is subject to delays due to resources being wasted on uninfected individuals. These delays become more detrimental as the presymptomatic transmission window becomes larger, so controllability tends to decrease as z increases. For negative z, however, some individuals become symptomatic while still in the exposed class, so efficacious clinical testing can be used to remove infected individuals with minimal delay before than can begin generating new transmissions. This is impossible under correlated symptoms or positive z values. The opportunity for clinical testing to remove preinfectious individuals increases as z grows in the negative direction, and controllability consequently increases. Notably, the increase in controllability can be significant for a negative z disease compared to a positive z disease. This observation may explain why the 2003 SARS outbreak (negative z disease) was far easier to control than the COVID-19 pandemic (positive z disease) (54).

The remaining controllability reducing factors are straightforwardly explained. Namely, a more transmissible disease (i.e. one with a larger R_0^{un}) is inherently more difficult to control than a less transmissible disease, and the larger number of secondary infections generated by an individual can be detrimental to control when limited resources force delays in testing and quarantine. Likewise, shorter latent periods leave less time to locate infected individuals before they begin generating transmissions, so testing and quarantine delays become more costly. These factors together help explain why the omicron variant has been particularly challenging to control (49, 55). The large R_0^{un} value is an oft emphasized contributing factor, but the short latent period relative to other variants can be just as important. Explicitly, comparing the generic disease (mean latent period 6 days) to the omicron variant (mean latent period 1.5 days) in Fig. 7 shows that omicron is roughly half as controllable despite both diseases having the same R_0^{un}.

4.3 Controllability, symptom onset, and the role of non-clinical testing

Our results across all model assumptions demonstrate a consistent clear relationship between non-clinical testing and controllability reducing factors unrelated to symptom onset assumptions: factors which reduce controllability also reduce the role of non-clinical testing in optimal strategies. We hypothesize that this relationship arises because wasted or inefficiently used resources are of greater

detriment in a less controllable system. That is, when a disease is considered less controllable, failure to utilize a quantity of testing capacity to identify and isolate infected individuals will result in a greater number of additional infections in comparison to a more controllable disease. With non-clinical testing, the beneficial impact of identifying removing non-symptomatic infected individuals is counterbalanced by the negative impact of potentially wasting tests on uninfected individuals, and the negative impact becomes more prominent as the disease becomes less controllable. Thus, optimal strategies place more emphasis on clinical testing which is guarantied to be utilized to identify and isolate an infected individual. However, for sufficiently large testing capacity, resources are plentiful enough such that wasting a test on an uninfected individual does not significantly delay or inhibit identification of infected individuals, so the role of non-clinical testing can be prominent in a less controllable disease, although still slightly diminished in comparison to a more controllable disease. Thus, the observed relationship between the role of non-clinical testing and controllability is closely tied to the resource limitation aspects of model.

In contrast to factors unrelated to symptom onset, the relationship between non-clinical testing controllability factors related to symptom onset assumptions is unclear. One one hand, one might expect that for a negative z disease like COVID-19, realistically modeling the incubation-latent offset will increase the role of of non-clinical testing in comparison to a model making the simpler correlated symptom assumption due to non-clinical testing's ability to capture presymptomatic spreaders. On the other hand, since the latent incubation offset decreases controllability for a negative z disease, one might expect non-clinical testing's role to be diminished due to the reasoning given in the preceding paragraph. We found that neither of these hypotheses are generally correct for guiding optimal strategies based on the results of simple ODE models. Instead, we found that age-of-infection modeling, and in particular, the details of the temporal offset between the incubation and latent periods, was critical to understanding disease progression, controllability, and optimal strategies for resource allocation.

Our results show that in reality, optimal policies for resource allocation depend on a complicated (often non-intuitive) interplay between incubation-latent offset, disease strength, and other characteristics like latent period length (Figs. 11, 12, 13, and the corresponding figures in the supplementary material). This is a critical observation because real-world public policies and attitudes towards a novel diseases are typically based on what has been successful for previous diseases com-

bined with basic intuition for the broad differences between the novel disease and previous diseases. For example, 2003 SARS has no presymptomatic transmission while COVID-19 has significant presymptomatic transmission, so one might intuitively expect that a successful strategy for controlling 2003 SARS should be adapted for COVID-19 by allocating more resources to non-clinical testing in order to capture presymptomatic spreaders, but this is not at all the case according to our results. Our work shows that this intuition-based approach to public policy can fail, and thus highlights the importance of mathematical modeling in helping to guide disease management. In particular, it is important to establish modeling frameworks where different diseases can be examined comparatively under the same lens to more closely mimic the way diseases are compared in the real world. Utilizing the age-of-infection to decouple symptom status from specific model compartments is the crucial element for allowing such comparisons in our model. Future models may build upon these ideas to incorporate not only the age-of-infection, but also the age-of-infectiousness in order to model additional realistic features like partial correlations between incubation, latent, and infectious period lengths as well as time-varying infectivity levels dependent on the time since infectiousness or symptom onset.

Acknowledgments

References

[1] World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020, 2020. [cited 2022 October 24]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020.

[2] World Health Organization. WHO COVID-19 Dashboard, 2020. [cited 2022 October 24]. Available from: https://covid19.who.int/.

[3] Antoine Mandel and Vipin Veetil. The economic cost of COVID lLockdowns: An out-of-eEquilibrium analysis. *Econ Disaster Clim Chang*, 4:431–451, 2020. doi: 10.1007/s41885-020-00066-z.

[4] Adam Rose. COVID-19 economic impacts in perspective: A comparison to recent U.S. disasters. *Int J Disaster Risk Reduct*, 60:102317, June 2021. doi: 10.1016/j.ijdrr.2021.102317.

[5] Eva Clark, Elizabeth Y Chiao, and E Susan Amirian. Why contact tracing efforts have failed to curb coronavirus disease 2019 (COVID-19) transmission in much of the United States. *Clin Infect Dis*, 72:e415–e419, 2021. doi: 10.1093/cid/ciaa1155.

[6] E. Susan Amirian. Prioritizing COVID-19 test utilization during supply shortages in the late phase pandemic. *J Public Health Policy*, 43:320–324, 2022. doi: 10.1057/s41271-022-00348-8.

[7] Centers for Disease Control and Prevention. Investigating a COVID-19 case, 2022. [cited 2022 October 24]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/investigating-covid-19-case.html.

[8] World Health Organization. Public health surveillance for COVID-19: Interim guidance, 2022. [cited 2022 October 24]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-SurveillanceGuidance-2022.2.

[9] William V. Padula. Why only test symptomatic patients? Consider random screening for COVID-19. *Appl Health Econ Health Policy*, 18:333–334, 2020. doi: 10.1007/s40258-020-00579-4.

[10] Hualei Xin, Yu Li, Peng Wu, Zhili Li, Eric H Y Lau, Ying Qin, Liping Wang, Benjamin J Cowling, Tim K Tsang, and Zhongjie Li. Estimating the latent period of coronavirus disease 2019 (COVID-19). *Clin Infect Dis*, 74:1678–1681, 2022. doi: 10.1093/cid/ciab746.

[11] Min Kang, Hualei Xin, Jun Yuan, Sheikh Taslim Ali, Zimian Liang, Jiayi Zhang, Ting Hu, Eric HY Lau, Yingtao Zhang, Meng Zhang, Benjamin J Cowling, Yan Li, and Peng Wu. Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta variant infections in Guangdong, China, May to June 2021. *Eurosurveillance*, 27, 2022. doi: 10.2807/1560-7917.ES.2022.27.10.2100815.

[12] Nathan W. Furukawa, John T. Brooks, and Jeremy Sobel. Evidence supporting transmission of severe acute respiratory syndrome coronavirus 2 while presymptomatic or asymptomatic. *Emerg Infect Dis*, 26:e201595, 2020. doi: 10.3201/eid2607.201595.

[13] Kieran A. Walsh, Karen Jordan, Barbara Clyne, Daniela Rohde, Linda Drummond, Paula Byrne, Susan Ahern, Paul G. Carty, Kirsty K. O'Brien, Eamon O'Murchu, Michelle O'Neill, Susan M. Smith, Mirn Ryan, and Patricia Harrington. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. *J Infect*, 81:357–371, 2020. doi: 10.1016/j.jinf.2020.06.067.

[14] Arabella Widders, Alex Broom, and Jennifer Broom. SARS-CoV-2: The viral shedding vs infectivity dilemma. *Infect Dis Health*, 25:210–215, 2020. doi: 10.1016/j.idh.2020.05.002.

[15] Qiuyue Ma, Jue Liu, Qiao Liu, Liangyu Kang, Runqing Liu, Wenzhan Jing, Yu Wu, and Min Liu. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: A systematic review and meta-analysis. *JAMA Netw Open*, 4:e2137257, 2021. doi: 10.1001/jamanetworkopen.2021.37257.

[16] Amin Yousefpour, Hadi Jahanshahi, and Stelios Bekiros. Optimal policies for control of the novel coronavirus disease (COVID-19) outbreak. *Chaos Solitons Fractals*, 136:109883, 2020. doi: 10.1016/j.chaos.2020.109883.

[17] Lautaro Vassallo, Ignacio A. Perez, Lucila G. Alvarez-Zuzek, Julin Amaya, Marcos F. Torres, Lucas D. Valdez, Cristian E. La Rocca, and Lidia A. Braunstein. An epidemic model for COVID-19 transmission in Argentina: Exploration of the alternating quarantine and massive testing strategies. *Math Biosci*, 346:108664, 2022. doi: 10.1016/j.mbs.2021.108664.

[18] Justin M. Calabrese and Jeffery Demers. How optimal allocation of limited testing capacity changes epidemic dynamics. *J Theor Biol*, 538:111017, 2022. doi: 10.1016/j.jtbi.2022.1110173.

[19] Alberto Olivares and Ernesto Staffetti. Optimal control-based vaccination and testing strategies for COVID-19. *Comput Methods Programs Biomede*, 211:106411, 2021. doi: 10.1016/j.cmpb.2021.106411.

[20] Steffen E. Eikenberry, Marina Mancuso, Enahoro Iboi, Tin Phan, Keenan Eikenberry, Yang Kuang, Eric Kostelich, and Abba B. Gumel. To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic. *Infect Dis Model*, 5:293–308, 2020. doi: 10.1016/j.idm.2020.04.001.

[21] Kristina P. Vatcheva, Josef Sifuentes, Tamer Oraby, Jose Campo Maldonado, Timothy Huber, and Mara Cristina Villalobos. Social distancing and testing as optimal strategies against the spread of COVID-19 in the Rio Grande Valley of Texas. *Infect Dis Model*, 6:729–742, 2021. doi: 10.1016/j.idm.2021.04.004.

[22] Calistus N. Ngonghala, Enahoro A. Iboi, and Abba B. Gumel. Could masks curtail the post-lockdown resurgence of COVID-19 in the US? *Mathl Biosci*, 329:108452, 2020. doi: 10.1016/j.mbs.2020.108452.

[23] Colin J. Worby and Hsiao-Han Chang. Face mask use in the general population and optimal resource allocation during the COVID-19 pandemic. *Nat Commun*, 11:4049, 2020. doi: 10.1038/s41467-020-17922-x.

[24] Sarah F. Poole, Jessica Gronsbell, Dale Winter, Stefanie Nickels, Roie Levy, Bin Fu, Maximilien Burq, Sohrab Saeb, Matthew D. Edwards, Michael K. Behr, Vignesh Kumaresan, Alexander R. Macalalad, Sneh Shah, Michelle Prevost, Nigel Snoad, Michael P. Brenner, Lance J. Myers, Paul Varghese, Robert M. Califf, Vindell Washington, Vivian S. Lee, and Menachem Fromer. A holistic approach for suppression of COVID-19 spread in workplaces and universities. *PLoS One*, 16:e0254798, 2021. doi: 10.1371/journal.pone.0254798.

[25] Joshua Kiddy K. Asamoah, Zhen Jin, Gui-Quan Sun, Baba Seidu, Ernest Yankson, Afeez Abidemi, F.T. Oduro, Stephen E. Moore, and Eric Okyere. Sensitivity assessment and optimal economic evaluation of a new COVID-19 compartmental epidemic model with control interventions. *Chaos Soliton Fractal*, 146:110885, 2021. doi: 10.1016/j.chaos.2021.110885.

[26] Paul J. Hurtado and Adam S. Kirosingh. Generalizations of the Linear Chain Trick: incorporating more flexible dwell time distributions into mean field ODE models. *J Math Biol*, 79(5): 1831–1883, 2019. doi: 10.1007/s00285-019-01412-w.

[27] Helen J Wearing, Pejman Rohani, and Matt J Keeling. Appropriate models for the management of infectious diseases. *PLoS Med*, 2:e174, 2005. doi: 10.1371/journal.pmed.0020174.

[28] Zhonglan Wu, David Harrich, Zhongyang Li, Dongsheng Hu, and Dongsheng Li. The unique

features of SARSCoV2 transmission: Comparison with SARSCoV, MERSCoV and 2009 H1N1 pandemic influenza virus. *Rev Med Virol*, 31:e2171, 2021. doi: 10.1002/rmv.2171.

[29] Guang Zeng, Shu-Yun Xie, Qin Li, and Jian-Ming Ou. Infectivity of severe acute respiratory syndrome during its incubation period. *Biomed Environ Sci*, 22:502–510, 2009. doi: 10.1016/S0895-3988(10)60008-6.

[30] Andrew William Byrne, David McEvoy, Aine B Collins, Kevin Hunt, Miriam Casey, Ann Barber, Francis Butler, John Griffin, Elizabeth A Lane, Conor McAloon, Kirsty O'Brien, Patrick Wall, Kieran A Walsh, and Simon J More. Inferred duration of infectious period of SARS-CoV-2: Rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. *BMJ Open*, 10:e039856, 2020. doi: 10.1136/bmjopen-2020-039856.

[31] Muge Cevik, Matthew Tate, Ollie Lloyd, Alberto Enrico Maraolo, Jenna Schafers, and Antonia Ho. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: A systematic review and meta-analysis. *Lancet Microbe*, 2:e13–e22, 2021. doi: 10.1016/S2666-5247(20)30172-5.

[32] Jantien A Backer, Don Klinkenberg, and Jacco Wallinga. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 2028 January 2020. *Eurosurveillance*, 25, 2020. doi: 10.2807/1560-7917.ES.2020.25.5.2000062.

[33] Stephen A. Lauer, Kyra H. Grantz, Qifang Bi, Forrest K. Jones, Qulu Zheng, Hannah R. Meredith, Andrew S. Azman, Nicholas G. Reich, and Justin Lessler. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. *Ann Intern Med*, 172:577–582, 2020. doi: 10.7326/M20-0504.

[34] Qun Li, Xuhua Guan, Peng Wu, Xiaoye Wang, Lei Zhou, Yeqing Tong, Ruiqi Ren, Kathy S.M. Leung, Eric H.Y. Lau, Jessica Y. Wong, Xuesen Xing, Nijuan Xiang, Yang Wu, Chao Li, Qi Chen, Dan Li, Tian Liu, Jing Zhao, Man Liu, Wenxiao Tu, Chuding Chen, Lianmei Jin, Rui Yang, Qi Wang, Suhua Zhou, Rui Wang, Hui Liu, Yinbo Luo, Yuan Liu, Ge Shao, Huan Li, Zhongfa Tao, Yang Yang, Zhiqiang Deng, Boxi Liu, Zhitao Ma, Yanping Zhang, Guoqing Shi, Tommy T.Y. Lam, Joseph T. Wu, George F. Gao, Benjamin J. Cowling, Bo Yang, Gabriel M.

Leung, and Zijian Feng. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med*, 382:1199–1207, 2020. doi: 10.1056/NEJMoa2001316.

[35] Conor McAloon, ine Collins, Kevin Hunt, Ann Barber, Andrew W Byrne, Francis Butler, Miriam Casey, John Griffin, Elizabeth Lane, David McEvoy, Patrick Wall, Martin Green, Luke O'Grady, and Simon J More. Incubation period of COVID-19: A rapid systematic review and meta-analysis of observational research. *BMJ Open*, 10:e039652, 2020. doi: 10.1136/bmjopen-2020-039652.

[36] Balram Rai, Anandi Shukla, and Laxmi Kant Dwivedi. Incubation period for COVID-19: A systematic review and meta-analysis. *J Public Health*, 2021. doi: 10.1007/s10389-021-01478-1.

[37] Hualei Xin, Jessica Y Wong, Caitriona Murphy, Amy Yeung, Sheikh Taslim Ali, Peng Wu, and Benjamin J Cowling. The incubation period distribution of coronavirus disease 2019: A systematic review and meta-analysis. *Clin Infect Dis*, 73:2344–2352, December 2021. doi: 10.1093/cid/ciab501.

[38] Hideo Tanaka, Tsuyoshi Ogata, Toshiyuki Shibata, Hitomi Nagai, Yuki Takahashi, Masaru Kinoshita, Keisuke Matsubayashi, Sanae Hattori, and Chie Taniguchi. Shorter incubation period among COVID-19 cases with the BA.1 Omicron variant. *Int J Environ Res Public Health*, 19:6330, 2022. doi: 10.3390/ijerph19106330.

[39] Lauren Jansen. Investigation of a SARS-CoV-2 B.1.1.529 (omicron) variant cluster Nebraska, NovemberDecember 2021. *MMWR. Morbidity and Mortality Weekly Report*, 70, 2021. doi: 10.15585/mmwr.mm705152e3.

[40] Javier Del guila Meja, Reinhard Wallmann, Jorge Calvo-Montes, Jess Rodrguez-Lozano, Trinidad Valle-Madrazo, and Adrian Aginagalde-Llorente. Secondary attack rate, transmission and incubation periods, and serial interval of SARS-CoV-2 Omicron variant, Spain. *Emerg Infect Dis*, 28:1224–1228, 2022. doi: 10.3201/eid2806.220158.

[41] Mina Park, Colleen Pawliuk, Tribesty Nguyen, Amanda Griffitt, Linda Dix-Cooper, Nadia Fourik, and Martin Dawes. Determining the communicable period of SARS-CoV-2: A rapid

review of the literature, March to September 2020. *Euro Surveil*, 26, 2021. doi: 10.2807/1560-7917.ES.2021.26.14.2001506.

[42] Yang Liu, Li-Meng Yan, Lagen Wan, Tian-Xin Xiang, Aiping Le, Jia-Ming Liu, Malik Peiris, Leo L M Poon, and Wei Zhang. Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect Dis*, 20:656–657, 2020. ISSN 14733099. doi: 10.1016/S1473-3099(20)30232-2.

[43] A. Maisa, G. Spaccaferri, L. Fournier, J. Schaeffer, J. Deniau, P. Rolland, B. Coignard, A. Andrieu, O. Broustal, S. Chene, S. Chent, E. Fougre, G. Gbaguidi, M. Hamidouche, A. Lamy, Q. Mano, B. Mastrovito, A. Mercier, G. Modenesi, G. Picard, J. Prudhomme, F. Rapilly, A. Riondel, M. Rivire, B. Villegas Ramirez, A. Zhu-Soubise, M. Zurbaran, A. Amzert, L. Andreoletti, A. Bal, R. Beaurepere, S. Behillil, L. Belec, C. Bernard, L. Bocket, L. Bouri, T. Bourlet, C. Bressollette-Bodin, S. Brichler, C. Brugerolles, S. Cado, V. Calvez, N. Capron, S. Castelain, J. Castro-Alvarez, M.-L. Chaix, C. Charpentier, D. Che, C. Chillou, P. Colson, P. Coudene, A. Crinquette, A. De Rougemont, H. Delagrverie, C. Delamare, T. Denecker-Berardino, D. Descamps, M. Desroches, G. Destras, G. Dos Santos, A. Ducancelle, S. Ducreux, T. Duret, V. Enouf, S. Fafi-Kremer, C. Felici, S. Fourati, P.-E. Fournier, C. Gaudy, H. Germain, V. Giordanengo, O. Gorge, S. Haim-Boukobza, C. Henquell, A. Holstein, L. Houhamdi, J. Izopet, V. Jacomo, A. Jacques, M.-C. Jaffar-Bandjee, M. Jimenez, L. Josset, S. Kemeny, M.-E. Lafon, A. Le Bars, G. Le Corguille, Q. Lepiller, A. Levasseur, N. Leveque, B. Lina, C. Madelaine, C. Malabat, S. Marque-Juillet, T. Martin-Dunavit, P. Mavingui, A. Merens, I. Messak, L. Morand-Joubert, X. Naudot, P. Neybecker, J.-M. Pawlotsky, L. Pilorge, J.-C. Plantier, C. Poggi, M. Pretet, C. Ragot, H. Raoul, S. Rogez, A.-M. Roque-Afonso, B. Roquebert, D. Rousset, F. Rozenberg, C. Sagot, S. Sahnoune, D. Salgado, O. Sand, C. Saudemont, E. Schvoerer, E. Simon-Loriere, R. Stephan, J. Sudour, V. Thibault, E. Tuaillon, A. Vabret, E. Vallee, S. Van Der Werf, J. Van Helden, L. Verdurme, A. Vignola, D. Wilkinson, and Y. Yazdanpanah. First cases of Omicron in France are exhibiting mild symptoms, November 2021January 2022. *Infect Dis Now*, 52:160–164, 2022. doi: 10.1016/j.idnow.2022.02.003.

[44] Andrew A Sayampanathan, Cheryl S Heng, Phua Hwee Pin, Junxiong Pang, Teoh Yee Leong, and Vernon J Lee. Infectivity of asymptomatic versus symptomatic COVID-19. *Lancet*, 397: 93–94, 2021. doi: 10.1016/S0140-6736(20)32651-9.

[45] Maimuna S Majumder and Kenneth D Mandl. Early in the epidemic: impact of preprints on global discourse about COVID-19 transmissibility. *Lancet Glob Health*, 8:e627–e630, 2020. doi: 10.1016/S2214-109X(20)30113-3.

[46] Ral Patricio Fernndez-Naranjo, Eduardo Vsconez-Gonzlez, Katherine Simbaa-Rivera, Lenin Gmez-Barreno, Juan S. Izquierdo-Condoy, Domnica Cevallos-Robalino, and Esteban Ortiz-Prado. Statistical data driven approach of COVID-19 in Ecuador: R0 and Rt estimation via new method. *Infect Dis Model*, 6:232–243, 2021. doi: 10.1016/j.idm.2020.12.012.

[47] Cheng-Jun Yu, Zi-Xiao Wang, Yue Xu, Ming-Xia Hu, Kai Chen, and Gang Qin. Assessment of basic reproductive number for COVID-19 at global level: A meta-analysis. *Medicine*, 100: e25837, 2021. doi: 10.1097/MD.0000000000025837.

[48] Ying Liu and Joacim Rocklv. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. *J Travel Med*, 28:taab124, 2021. doi: 10.1093/jtm/taab124.

[49] Talha Khan Burki. Omicron variant and booster COVID-19 vaccines. *Lancet Respir Med*, 10: e17, 2022. doi: 10.1016/S2213-2600(21)00559-2.

[50] Ying Liu and Joacim Rocklv. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta. *J Travel Med*, 29:taac037, 2022. doi: 10.1093/jtm/taac037.

[51] Yoshiaki Gu, Nobuhiro Komiya, Hajime Kamiya, Yoshinori Yasui, Kiyosu Taniguchi, and Nobuhiko Okabe. Pandemic (H1N1) 2009 transmission during presymptomatic phase, Japan. *Emerg Infect Dis*, 17:1737–1739, 2011. doi: 10.3201/eid1709.101411.

[52] F. T. M. Freitas, A. P. S. Cabral, E. N. C. Barros, M. J. O. Burigo, R. D. Prochnow, L. A. Silva, M. A. Widdowson, and J. Sobel. Pre-symptomatic transmission of pandemic influenza H1N1 2009: investigation of a family cluster, Brazil. *Epidemiol Infect*, 141:763–766, 2013. doi: 10.1017/S0950268812001501.

[53] J.C. Lopez-Marcos. An upwind scheme for a nonlinear hyperbolic integro-differential equa-

tion with integral boundary condition. *Comput Math Appl*, 22:15–28, 1991. doi: 10.1016/0898-1221(91)90030-8.

[54] Monica Gandhi, Deborah S. Yokoe, and Diane V. Havlir. Asymptomatic transmission, the Achilles heel of current strategies to control Covid-19. *N Engl J Med*, 382:2158–2160, 2020. doi: 10.1056/NEJMe2009758.

[55] Luke Taylor. Covid-19: Hong Kong reports worlds highest death rate as zero covid strategy fails. *BMJ*, page o707, 2022. doi: 10.1136/bmj.o707.